Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Weeks after earning CEO's stamp of approval, a Novartis skin drug loses head-to-head battle with standard of care
With a jam-packed pipeline to parse, Novartis chief Vas Narasimhan has helped investors out in the past by highlighting a few key programs his team thinks could be easy winners. One of those drugs has now hit the skids in two late-stage tests, losing some of its luster as a potential centerpiece medicine moving ahead.
Novartis’ ligelizumab, a “high-affinity” anti-immunoglobulin E antibody failed to beat out standard-of-care Xolair — its own partnered drug with Genentech — in two Phase III studies in patients with the skin disease chronic spontaneous urticaria, the company said Monday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters